Kala Pharmaceuticals, Inc

(NASDAQ:KALA)

Latest On Kala Pharmaceuticals, Inc (KALA):

Date/Time Type Description Signal Details
2023-04-28 20:55 ESTNewsKala's Combangio granted $15M by CIRM for development of KPI-012, stock rises 9%N/A
2023-04-12 18:51 ESTNewsKala stock rises on FDA fast track status for KPI-012 for rare eye disorderN/A
2023-03-29 14:25 ESTNewsKala pharmaceuticals appoints Francis Mah as Chief Medical AdvisorN/A
2023-03-06 15:45 ESTNewsKala jumps 26% to extend gains after Q4 2022 updateN/A
2023-03-03 23:09 ESTNewsKala Pharmaceuticals GAAP EPS of -$7.97 misses by $1.42N/A
2023-01-19 07:49 ESTNewsKala Pharma: Rare Eye Disease Biotech Lottery Ticket Based On Stem Cell PlatformN/A
2023-01-14 11:25 ESTNewsStocks To Watch: Economic Reports, Earnings Blockbusters And Political Minefields Lie Ahead Next WeekN/A
2022-12-31 15:00 ESTNewsStocks To Watch: Spotlight On Tesla, Nio, Walgreens And Constellation BrandsN/A
2022-12-29 04:59 ESTNewsKala Pharma shares more than triple in value on new drug application nod, financingN/A
2022-12-27 23:33 ESTNewsKala Pharma soars ~60% after hours as FDA oks application for corneal defect treatmentN/A
2022-11-29 07:54 ESTNewsKala Pharmaceuticals enters into private placement financing for up to $31MN/A
2022-11-29 07:54 ESTNewsKala jumps ~21% on new drug application submission to FDA for corneal defect treatmentN/A
2022-11-10 01:57 ESTNewsKala Pharma jumps 33% after Q3 updatesN/A
2022-11-08 14:27 ESTNewsKala Pharmaceuticals GAAP EPS of $19.25, revenue of $0.42MN/A
2022-10-20 18:09 ESTNewsKala Pharmaceuticals to execute reverse stock splitN/A
2022-09-17 05:24 ESTNewsKala Pharrmaceuticals Investor Presentation - SlideshowN/A
2022-08-12 21:04 ESTNewsKala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-11 11:23 ESTNewsKala Pharmaceuticals GAAP EPS of -$0.38, revenue of $2.1MN/A
2022-08-11 11:23 ESTNewsKala Pharma sees large fall in operating expenses for H2, FY, extends expected cash runwayN/A
2022-08-10 19:01 ESTNewsKala Pharmaceuticals Q2 2022 Earnings PreviewN/A
2022-05-23 23:02 ESTNewsKala Pharmaceuticals plans to sell EYSUVIS and INVELTYS to AlconN/A
2022-05-18 08:55 ESTNewsKala Pharmaceuticals, Inc.'s (KALA) CEO Mark Iwicki on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-16 14:04 ESTNewsKala Pharmaceuticals GAAP EPS of -$0.45 misses by $0.11, revenue of $1.37M misses by $1.51MN/A
2022-05-16 14:04 ESTNewsKala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-16 14:04 ESTNewsKala stock rises despite Q1 earnings missN/A
2022-05-13 18:22 ESTNewsKala Pharmaceuticals Q1 2022 Earnings PreviewN/A
2022-05-03 16:15 ESTNewsKala expands commercial, Medicare coverage for dry eye disease therapy EysuvisN/A
2022-03-30 19:58 ESTNewsKala downgraded to underweight at JP Morgan on disappointing dry eye launchN/A
2022-03-30 03:23 ESTNewsKala Pharmaceuticals GAAP EPS of -$0.68 misses by $0.29, revenue of $1.87M misses by $1.55MN/A
2022-03-30 03:23 ESTNewsKala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-30 03:23 ESTNewsKala Pharmaceuticals stock falls 13% as Q4 net loss widens, revenue declines Y/YN/A
2022-03-08 15:40 ESTNewsKala's dry eye drug Eysuvis gets coverage by UnitedHealthcare Commercial, Cigna MedicareN/A
2022-01-11 14:08 ESTNewsKala Pharmaceuticals (KALA) Investor Presentation (Slideshow)N/A
2021-12-13 22:03 ESTNewsNasdaq Biotechnology rejig: VTRS, NVCR among added, KALA, VYNE among deletedN/A
2021-11-16 03:14 ESTNewsKala Pharmaceuticals EPS in-line, misses on revenueN/A
2021-11-16 03:14 ESTNewsKala Pharma acquires Combangio gaining corneal defect candidateN/A
2021-11-16 03:13 ESTNewsKala Pharmaceuticals' (KALA) CEO Mark Iwicki on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-16 03:13 ESTNewsKala Pharmaceuticals, Inc. 2021 Q3 - Results - Earnings Call PresentationN/A
2021-11-12 23:25 ESTNewsKala Pharmaceuticals Q3 2021 Earnings PreviewN/A
2021-09-21 22:10 ESTNewsKala Pharmaceuticals (KALA) Investor Presentation - SlideshowN/A
2021-08-29 19:58 ESTNewsStaying Patient With Kala PharmaceuticalsN/A
2021-08-24 05:37 ESTNewsKala Pharmaceuticals (KALA) Corporate Overview - SlideshowN/A
2021-08-06 05:27 ESTNewsKala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-05 07:07 ESTNewsKala Pharmaceuticals EPS misses by $0.13, misses on revenueN/A
2021-05-05 18:27 ESTNewsKala Pharmaceuticals EPS misses by $0.01, misses on revenueN/A
2021-05-05 18:27 ESTNewsKala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q1 2021 Results - Earnings Call TranscriptN/A
2021-04-25 06:57 ESTNewsKala Pharmaceuticals: Eye Treatment Specialist With Much To Prove May Have Just The ProductN/A
2021-04-25 06:57 ESTNewsKala Pharmaceuticals Has Good Short- And Long-Term ProspectsN/A
2021-03-18 00:59 ESTNewsKala Pharmaceuticals (KALA) Presents At Oppenheimer 31st Annual Healthcare Conference - SlideshowN/A
2021-02-28 23:51 ESTAnalyst RatingThe Analyst Target Price has decreased from $21.5 to $21.33.Neutral

About Kala Pharmaceuticals, Inc (KALA):

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's product candidates include EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development programs comprise KPI-285/KPI-286, a receptor tyrosine kinase inhibitor program for the treatment of various retinal diseases; SEGRM program, a novel class of compounds designed to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway; and surface targeted steroid program (KPI-333), a new chemical entity as a topical steroid that targets the ocular surface. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.

KALA Quotes by TradingView

See Advanced Chart

General

  • Name Kala Pharmaceuticals, Inc
  • Symbol KALA
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 188
  • Fiscal Year EndDecember
  • IPO Date2017-07-20
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://www.kalarx.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 65.78
  • Price/Book (Most Recent Quarter) 4.92
  • Enterprise Value Revenue 69.03
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.76
  • Next Year EPS Estimate -$0.66
  • Next Quarter EPS Estimate -$0.78
  • Operating Margin -1497%
  • Return on Assets -32%
  • Return on Equity -161%
  • Revenue 6.36 million
  • Earnings Per Share -$2.87
  • Revenue Per Share $0.12
  • Gross Profit 4.19 million
  • Quarterly Earnings Growth 89.7%
View More

Highlights

  • Market Capitalization 493.03 million
  • EBITDA -84957000
  • PE Ratio -2.05
  • Analyst Target Price $21.33
  • Book Value Per Share $1.70
View More

Share Statistics

  • Shares Outstanding 61.55 million
  • Shares Float 39.38 million
  • % Held by Insiders 101%
  • % Held by Institutions 81.46%
  • Shares Short 10.59 million
  • Shares Short Prior Month 9.34 million
  • Short Ratio 4.18
  • Short % of Float 24%
  • Short % of Shares Outstanding 17%
View More

Technicals

  • Beta 0.39
  • 52 Week High $14.68
  • 52 Week Low $6.07
  • 50 Day Moving Average 8.22
  • 200 Day Moving Average 7.82
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Kala Pharmaceuticals, Inc (KALA) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Kala Pharmaceuticals, Inc (KALA) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-25$N/A-$0.55-$0.45-22.44%
2020-09-302020-11-05$N/A-$0.50-$0.45-10.21%
2020-06-302020-08-06$N/A-$0.42-$0.38-11.41%
2020-03-312020-05-07$N/A-$0.54-$0.45-20%
2019-12-312020-02-12$1.18 million-$0.63-$0.62-1.19%
2019-09-302019-11-07$N/A-$0.68-$0.65-4.97%
2019-06-302019-08-06$2.06 million-$0.70-$0.745.6%
2019-03-312019-05-09$1.39 million-$0.75-$0.816.88%
2018-12-312019-03-11$N/A-$0.75-$0.53-39.99%
2018-09-302018-11-08$N/A-$0.63-$0.641.56%
2018-06-302018-08-09$N/A-$0.60-$0.49-21.63%
2018-03-312018-05-10$N/A-$0.46-$0.460.65%
2017-12-312018-03-26$N/A-$0.46-$0.38-21.12%
2017-09-302017-11-07$N/A-$0.56-$0.43-31.76%
2017-06-302017-08-31$N/A-$9.30-$2.81-230.67%

Kala Pharmaceuticals, Inc (KALA) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Kala Pharmaceuticals, Inc (KALA) Chart:

KALA chart by TradingView

Kala Pharmaceuticals, Inc (KALA) News:

Below you will find a list of latest news for Kala Pharmaceuticals, Inc (KALA) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Kala Pharmaceuticals, Inc (KALA) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest KALA Trades:

Date Shares Price
Jun 13, 2022 7:35 PM EST100$0.3562
Jun 13, 2022 7:48 PM EST100$0.3575
Jun 13, 2022 7:50 PM EST200$0.3578
Jun 13, 2022 7:50 PM EST17$0.3578
Jun 13, 2022 7:50 PM EST295$0.3578

Kala Pharmaceuticals, Inc (KALA) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000110465920078332/0001104659-20-078332-index.htm
2018-08-15UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1479419/000000000018025276/0000000000-18-025276-index.htm
2020-05-13UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1479419/000000000020004214/0000000000-20-004214-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1479419/000084608719000053/0000846087-19-000053-index.htm
2018-08-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1479419/000090221918000490/0000902219-18-000490-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1479419/000090221919000317/0000902219-19-000317-index.htm
2018-10-02424B2Prospectus [Rule 424(b)(2)]https://www.sec.gov/Archives/edgar/data/1479419/000104746918006543/0001047469-18-006543-index.htm
2018-10-03424B2Prospectus [Rule 424(b)(2)]https://www.sec.gov/Archives/edgar/data/1479419/000104746918006555/0001047469-18-006555-index.htm
2020-03-11424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1479419/000104746920001367/0001047469-20-001367-index.htm
2020-03-12424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1479419/000104746920001398/0001047469-20-001398-index.htm
2020-05-07S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1479419/000104746920002892/0001047469-20-002892-index.htm
2018-08-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000110465918053380/0001104659-18-053380-index.htm
2018-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000110465918060021/0001104659-18-060021-index.htm
2018-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000110465918060023/0001104659-18-060023-index.htm
2018-10-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000110465918060617/0001104659-18-060617-index.htm
2018-10-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000110465918062242/0001104659-18-062242-index.htm
2019-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000110465919033349/0001104659-19-033349-index.htm
2019-06-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000110465919034520/0001104659-19-034520-index.htm
2019-06-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000110465919034521/0001104659-19-034521-index.htm
2019-06-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000110465919034522/0001104659-19-034522-index.htm
2019-06-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000110465919034523/0001104659-19-034523-index.htm
2019-06-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000110465919034524/0001104659-19-034524-index.htm
2019-06-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000110465919034526/0001104659-19-034526-index.htm
2019-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000110465919044885/0001104659-19-044885-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000110465920003222/0001104659-20-003222-index.htm
2020-02-13S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1479419/000110465920019389/0001104659-20-019389-index.htm
2020-03-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000110465920030426/0001104659-20-030426-index.htm
2020-03-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000110465920031555/0001104659-20-031555-index.htm
2020-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000110465920032036/0001104659-20-032036-index.htm
2020-03-13SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1479419/000110465920033242/0001104659-20-033242-index.htm
2020-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000110465920033391/0001104659-20-033391-index.htm
2020-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000110465920033392/0001104659-20-033392-index.htm
2020-04-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000110465920044480/0001104659-20-044480-index.htm
2020-05-15CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1479419/000110465920062530/0001104659-20-062530-index.htm
2020-06-25S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1479419/000110465920076852/0001104659-20-076852-index.htm
2020-06-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000110465920077452/0001104659-20-077452-index.htm
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000110465920078271/0001104659-20-078271-index.htm
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000110465920078279/0001104659-20-078279-index.htm
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000110465920078287/0001104659-20-078287-index.htm
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000110465920078309/0001104659-20-078309-index.htm
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000110465920078310/0001104659-20-078310-index.htm
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000110465920078317/0001104659-20-078317-index.htm
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000110465920078319/0001104659-20-078319-index.htm
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000110465920078323/0001104659-20-078323-index.htm
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000110465920078325/0001104659-20-078325-index.htm
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000110465920078326/0001104659-20-078326-index.htm
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000110465920078327/0001104659-20-078327-index.htm
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000110465920078328/0001104659-20-078328-index.htm
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000110465920078330/0001104659-20-078330-index.htm
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000110465920078332/0001104659-20-078332-index.htm
2018-10-05SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1479419/000114420418052764/0001144204-18-052764-index.htm
2018-10-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000114420418052767/0001144204-18-052767-index.htm
2018-10-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000114420418052768/0001144204-18-052768-index.htm
2018-10-12SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1479419/000114420418053658/0001144204-18-053658-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1479419/000117266119000440/0001172661-19-000440-index.htm
2018-04-093Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911018005505/0001179110-18-005505-index.htm
2018-04-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911018005506/0001179110-18-005506-index.htm
2018-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911018008522/0001179110-18-008522-index.htm
2018-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911018008523/0001179110-18-008523-index.htm
2018-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911018008525/0001179110-18-008525-index.htm
2018-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911018008526/0001179110-18-008526-index.htm
2018-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911018008527/0001179110-18-008527-index.htm
2018-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911018008573/0001179110-18-008573-index.htm
2018-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911018008574/0001179110-18-008574-index.htm
2018-10-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911018012105/0001179110-18-012105-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911019000455/0001179110-19-000455-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911019000457/0001179110-19-000457-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911019000459/0001179110-19-000459-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911019000460/0001179110-19-000460-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911019000461/0001179110-19-000461-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911019000462/0001179110-19-000462-index.htm
2019-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911019011016/0001179110-19-011016-index.htm
2019-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911019011017/0001179110-19-011017-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911020000154/0001179110-20-000154-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911020000156/0001179110-20-000156-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911020000157/0001179110-20-000157-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911020000158/0001179110-20-000158-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911020000160/0001179110-20-000160-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911020000161/0001179110-20-000161-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911020003675/0001179110-20-003675-index.htm
2020-03-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911020003841/0001179110-20-003841-index.htm
2020-04-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911020004335/0001179110-20-004335-index.htm
2020-04-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911020004834/0001179110-20-004834-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911020007239/0001179110-20-007239-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911020007674/0001179110-20-007674-index.htm
2020-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911020010706/0001179110-20-010706-index.htm
2020-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911020010707/0001179110-20-010707-index.htm
2020-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911020010708/0001179110-20-010708-index.htm
2020-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911020010709/0001179110-20-010709-index.htm
2020-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911020010710/0001179110-20-010710-index.htm
2020-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1479419/000117911020010711/0001179110-20-010711-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1479419/000119312519037954/0001193125-19-037954-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1479419/000119312520033356/0001193125-20-033356-index.htm
2020-03-23SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1479419/000119312520082611/0001193125-20-082611-index.htm
2018-04-0210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1479419/000155837018002697/0001558370-18-002697-index.htm
2018-04-02S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1479419/000155837018002698/0001558370-18-002698-index.htm
2018-04-25DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1479419/000155837018003249/0001558370-18-003249-index.htm
2018-04-26DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1479419/000155837018003328/0001558370-18-003328-index.htm
2018-05-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000155837018004568/0001558370-18-004568-index.htm
2018-05-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1479419/000155837018004674/0001558370-18-004674-index.htm
2018-06-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000155837018005283/0001558370-18-005283-index.htm
2018-08-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000155837018006825/0001558370-18-006825-index.htm
2018-08-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1479419/000155837018006883/0001558370-18-006883-index.htm
2018-08-09S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1479419/000155837018006917/0001558370-18-006917-index.htm
2018-08-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000155837018007113/0001558370-18-007113-index.htm
2018-08-20S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1479419/000155837018007159/0001558370-18-007159-index.htm
2018-08-20CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1479419/000155837018007161/0001558370-18-007161-index.htm
2018-08-23CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1479419/000155837018007195/0001558370-18-007195-index.htm
2018-09-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000155837018007359/0001558370-18-007359-index.htm
2018-10-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000155837018007676/0001558370-18-007676-index.htm
2018-11-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000155837018008253/0001558370-18-008253-index.htm
2018-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000155837018009002/0001558370-18-009002-index.htm
2018-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1479419/000155837018009054/0001558370-18-009054-index.htm
2018-12-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000155837018009767/0001558370-18-009767-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000155837019000060/0001558370-19-000060-index.htm
2019-03-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000155837019001781/0001558370-19-001781-index.htm
2019-03-1210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1479419/000155837019001825/0001558370-19-001825-index.htm
2019-03-12S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1479419/000155837019001827/0001558370-19-001827-index.htm
2019-04-12DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1479419/000155837019002956/0001558370-19-002956-index.htm
2019-04-12DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1479419/000155837019002961/0001558370-19-002961-index.htm
2019-05-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000155837019004563/0001558370-19-004563-index.htm
2019-05-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1479419/000155837019004703/0001558370-19-004703-index.htm
2019-06-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000155837019005587/0001558370-19-005587-index.htm
2019-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000155837019007149/0001558370-19-007149-index.htm
2019-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1479419/000155837019007251/0001558370-19-007251-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000155837019010281/0001558370-19-010281-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1479419/000155837019010366/0001558370-19-010366-index.htm
2020-02-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000155837020000702/0001558370-20-000702-index.htm
2020-02-1210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1479419/000155837020000733/0001558370-20-000733-index.htm
2020-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1479419/000155837020004558/0001558370-20-004558-index.htm
2020-04-29DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1479419/000155837020004560/0001558370-20-004560-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000155837020005533/0001558370-20-005533-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1479419/000155837020005698/0001558370-20-005698-index.htm
2020-05-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000155837020006941/0001558370-20-006941-index.htm
2020-06-10DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1479419/000155837020007408/0001558370-20-007408-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000155837020009498/0001558370-20-009498-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1479419/000155837020009714/0001558370-20-009714-index.htm
2020-09-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000155837020011192/0001558370-20-011192-index.htm
2020-10-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000155837020011765/0001558370-20-011765-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1479419/000155837020012691/0001558370-20-012691-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1479419/000155837020012835/0001558370-20-012835-index.htm
2018-08-27EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1479419/999999999518002212/9999999995-18-002212-index.htm
2020-05-19EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1479419/999999999520001204/9999999995-20-001204-index.htm
2018-04-19CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1479419/999999999718004980/9999999997-18-004980-index.htm
2018-08-22CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1479419/999999999718007412/9999999997-18-007412-index.htm
2018-10-09CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1479419/999999999718008524/9999999997-18-008524-index.htm
2020-05-01CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1479419/999999999720002358/9999999997-20-002358-index.htm

Kala Pharmaceuticals, Inc (KALA) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Kala Pharmaceuticals, Inc (KALA). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 101%
Institutional Ownership: 8146%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-03-16Todd BazemoreChief Operating OfficerBuy10,000.005.7557,500.0010,000.00https://www.sec.gov/Archives/edgar/data/1479419/000117911020003841/0001179110-20-003841-index.htm
2020-06-25Hongming ChenChief Scientific OfficerBuy16,000.00102,849.00https://www.sec.gov/Archives/edgar/data/1479419/000110465920078279/0001104659-20-078279-index.htm
2020-10-26Eric TrachtenbergOfficerBuy61,000.00105,901.00https://www.sec.gov/Archives/edgar/data/1479419/000117911020010710/0001179110-20-010710-index.htm
2020-03-13RA CAPITAL MANAGEMENT, L.P.DirectorBuy6,337,135.007.8949,999,995.1510,874,613.00https://www.sec.gov/Archives/edgar/data/1479419/000110465920033391/0001104659-20-033391-index.htm
2020-03-13Rajeev M. ShahDirectorBuy6,337,135.007.8949,999,995.1510,874,613.00https://www.sec.gov/Archives/edgar/data/1479419/000110465920033392/0001104659-20-033392-index.htm
2020-10-26Todd BazemoreChief Operating OfficerBuy81,000.00110,000.00https://www.sec.gov/Archives/edgar/data/1479419/000117911020010711/0001179110-20-010711-index.htm
2020-04-09Romulus K BrazzellChief Medical OfficerBuy1,880.000.681,278.40110,605.00https://www.sec.gov/Archives/edgar/data/1479419/000117911020004834/0001179110-20-004834-index.htm
2020-10-26Mary ReumuthChief Financial OfficerBuy61,000.00125,293.00https://www.sec.gov/Archives/edgar/data/1479419/000117911020010706/0001179110-20-010706-index.htm
2020-04-09Romulus K BrazzellChief Medical OfficerBuy18,247.002.3041,968.10128,852.00https://www.sec.gov/Archives/edgar/data/1479419/000117911020004834/0001179110-20-004834-index.htm
2020-06-09Mary ReumuthChief Financial OfficerBuy11,520.002.3026,496.0016,336.00https://www.sec.gov/Archives/edgar/data/1479419/000117911020007239/0001179110-20-007239-index.htm
2020-10-26Hongming ChenChief Scientific OfficerBuy61,000.00163,849.00https://www.sec.gov/Archives/edgar/data/1479419/000117911020010709/0001179110-20-010709-index.htm
2020-04-09Romulus K BrazzellChief Medical OfficerBuy47,644.003.34159,130.96176,496.00https://www.sec.gov/Archives/edgar/data/1479419/000117911020004834/0001179110-20-004834-index.htm
2020-06-25Romulus K BrazzellChief Medical OfficerBuy19,000.00195,496.00https://www.sec.gov/Archives/edgar/data/1479419/000110465920078309/0001104659-20-078309-index.htm
2020-06-25GREGORY D PERRYDirectorBuy20,000.0020,000.00https://www.sec.gov/Archives/edgar/data/1479419/000110465920078327/0001104659-20-078327-index.htm
2020-06-25Gregory GrunbergDirectorBuy20,000.0020,000.00https://www.sec.gov/Archives/edgar/data/1479419/000110465920078310/0001104659-20-078310-index.htm
2020-06-25Rajeev M. ShahDirectorBuy20,000.0020,000.00https://www.sec.gov/Archives/edgar/data/1479419/000110465920078330/0001104659-20-078330-index.htm
2020-06-25Robert Bradley PaullDirectorBuy20,000.0020,000.00https://www.sec.gov/Archives/edgar/data/1479419/000110465920078319/0001104659-20-078319-index.htm
2020-06-09Mary ReumuthChief Financial OfficerBuy5,077.005.2126,451.1721,413.00https://www.sec.gov/Archives/edgar/data/1479419/000117911020007239/0001179110-20-007239-index.htm
2020-10-26Mark T IwickiChief Executive OfficerBuy178,300.00227,860.00https://www.sec.gov/Archives/edgar/data/1479419/000117911020010707/0001179110-20-010707-index.htm
2020-06-25Howard B RosenDirectorBuy20,000.0024,824.00https://www.sec.gov/Archives/edgar/data/1479419/000110465920078326/0001104659-20-078326-index.htm
2020-03-13Gregory GrunbergDirectorBuy2,534,854.007.8919,999,998.062,534,854.00https://www.sec.gov/Archives/edgar/data/1479419/000117911020003675/0001179110-20-003675-index.htm
2020-10-26Romulus K BrazzellChief Medical OfficerBuy81,000.00276,496.00https://www.sec.gov/Archives/edgar/data/1479419/000117911020010708/0001179110-20-010708-index.htm
2020-06-25ANDREW I KOVENDirectorBuy28,000.0028,000.00https://www.sec.gov/Archives/edgar/data/1479419/000110465920078287/0001104659-20-078287-index.htm
2018-10-05Gregory GrunbergDirectorBuy606,060.008.254,999,995.002,877,006.00https://www.sec.gov/Archives/edgar/data/1479419/000117911018012105/0001179110-18-012105-index.htm
2019-08-19Howard B RosenDirectorBuy2,880.000.681,958.402,880.00https://www.sec.gov/Archives/edgar/data/1479419/000110465920078325/0001104659-20-078325-index.htm
2020-06-19Eric TrachtenbergOfficerBuy28,901.005.19149,996.1928,901.00https://www.sec.gov/Archives/edgar/data/1479419/000117911020007674/0001179110-20-007674-index.htm
2020-06-25Todd BazemoreChief Operating OfficerBuy19,000.0029,000.00https://www.sec.gov/Archives/edgar/data/1479419/000110465920078271/0001104659-20-078271-index.htm
2020-06-09Mary ReumuthChief Financial OfficerBuy15,360.002.3035,328.0036,773.00https://www.sec.gov/Archives/edgar/data/1479419/000117911020007239/0001179110-20-007239-index.htm
2020-10-22Todd BazemoreChief Operating OfficerBuy40.007.60304.0042.00https://www.sec.gov/Archives/edgar/data/1479419/000117911020010711/0001179110-20-010711-index.htm
2020-06-25Eric TrachtenbergOfficerBuy16,000.0044,901.00https://www.sec.gov/Archives/edgar/data/1479419/000110465920078332/0001104659-20-078332-index.htm
2018-10-03RA CAPITAL MANAGEMENT, LLCDirectorBuy2,424,242.008.2519,999,996.504,537,478.00https://www.sec.gov/Archives/edgar/data/1479419/000114420418052767/0001144204-18-052767-index.htm
2018-10-03Rajeev M. ShahDirectorBuy2,424,242.008.2519,999,996.504,537,478.00https://www.sec.gov/Archives/edgar/data/1479419/000114420418052768/0001144204-18-052768-index.htm
2019-08-19Howard B RosenDirectorBuy1,944.000.47913.684,824.00https://www.sec.gov/Archives/edgar/data/1479419/000110465920078325/0001104659-20-078325-index.htm
2020-06-09Mary ReumuthChief Financial OfficerBuy11,520.002.3026,496.0048,293.00https://www.sec.gov/Archives/edgar/data/1479419/000117911020007239/0001179110-20-007239-index.htm
2020-06-25Mark T IwickiChief Executive OfficerBuy49,560.0049,560.00https://www.sec.gov/Archives/edgar/data/1479419/000110465920078323/0001104659-20-078323-index.htm
2020-06-25Mary ReumuthChief Financial OfficerBuy16,000.0064,293.00https://www.sec.gov/Archives/edgar/data/1479419/000110465920078328/0001104659-20-078328-index.htm
2019-05-30Howard B RosenDirectorBuy5,000.005.4227,100.008,240.00https://www.sec.gov/Archives/edgar/data/1479419/000110465919033349/0001104659-19-033349-index.htm
2020-03-30Hongming ChenChief Scientific OfficerBuy31,000.002.3071,300.0086,849.00https://www.sec.gov/Archives/edgar/data/1479419/000117911020004335/0001179110-20-004335-index.htm